Table 2

Trial Name and Design	Cell Line	Sample Size (n)	Cell Dose	Days to Admin Post MI	Route of Admin	Imaging Modality	Primary End Point
TOPCARE-AMI [23] (2002)	BMC OR CPC	59	BMC: 2.13 ± 75 × 10⁸ CPC: 0.16 ± 12 × 10⁸	4.9 ± 1.5	IC	LV angiogram MRI	•Increased LVEF • Decreased ESV •Reduced infarct size (4 months and 1 year)
BOOST [41] (RCT 2004)	BMC	60	24.6 ± 9.4 × 10⁸	4.8 ± 1.3	IC	MRI	•Increased LVEF by 6% over control (At 6 months)
REPAIR–AMI [42] (RCT 2006)	BMC	204	2.4 ± 1.7 × 10⁸	4.3 ± 1.3	IC	LV angiogram	•Increased LVEF by 2.5% over control(At 4 months)
FINCELL [43] (RCT 2008)	BMC	80	3.6 × 10⁸ (median)	2-6	IC	LV angiogram	•Increased LVEF by 5% over control(At 6 months)

All values are mean ± SD unless stated

Table 2: Abbreviations: TOPCARE-AMI Trial: Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction Trial; REPAIR-AMI Trial: Reinfusion of Enriched Progenitor Cells and Infarct Remodeling in Acute Myocardial Infarction Trial; BOOST Trial: Intracoronary autologous bone-marrow cell transfer after myocardial infarction; RCT: Randomized control trial All values are mean ± SD unless stated.